A network meta-analysis depicted that R40bid and E40bid may be the optimum dosage to raise the cure rate of Helicobacter pylori (H. pylori) illness. Researchers sought to thoroughly compare the safety and effectiveness of various doses of Esomeprazole and Rabeprazole to treat H. pylori infection.

Databases such as PubMed, the Cochrane Central Registry for Controlled Trials (CENTRAL), and EMBASE were explored for searching relevant randomized controlled trials (RCTs) on Rabeprazole and Esomeprazole at various doses.

STATA 14.0 was used to perform network meta-analyses after the risk of bias evaluation and data extraction. For ranking the regimens, the surface under the cumulative ranking (SUCRA) was computed. Overall, 13 studies comprising 14 reports were incorporated. There were six different doses encompassing Rabeprazole 10 mg (R10bid), 20 mg (R20bid), and 40 mg (R40bid) 2 times a day, as well as Esomeprazole 20 mg (E20bid), 40 mg (E40bid) 2 times a day, and 40 mg once a day (E40qd). According to network meta-analysis, R40bid was the drug with the highest cure rate (83.8%).

This was subsequently followed by E40bid (82.6%), E20bid (54.5%), R20bid (34.2%), R10bid (22.8%), and E40qd (22.0%). E40qd exhibited the greatest rate of adverse events (91.1%), followed by R20bid (57.8%), R10bid (57.6%), E20bid (38.9%), E40bid (34.2%), and R40bid (20.4%). A sensitivity assessment verified the reliability of these findings. R40bid and E40bid may be the best dosages to enhance the cure rate, according to the evidence available. But, E40qd was superior for side effects. Future research must confirm these findings.